U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H21FN2O
Molecular Weight 324.3927
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESCITALOPRAM

SMILES

CN(C)CCC[C@]1(c2ccc(cc2)F)c3ccc(cc3CO1)C#N

InChI

InChIKey=WSEQXVZVJXJVFP-FQEVSTJZSA-N
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H21FN2O
Molecular Weight 324.3927
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Escitalopram, also known by the brand names Lexapro and Cipralex among others, is an antidepressant. The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Escitalopram is at least 100-fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake and inhibition of 5-HT neuronal firing rate. LEXAPRO (escitalopram) is indicated for the treatment of major depressive disorder and generalized anxiety disorder .

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LEXAPRO

Approved Use

INDICATIONS & USAGE Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for: Acute and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and adolescents aged 12 to 17 years (1.1) Acute Treatment of Generalized Anxiety Disorder (GAD) in adults (1.2) Escitalopram tablets USP are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age.

Launch Date

1.02928318E12
Primary
LEXAPRO

Approved Use

Lexapro® is a selective serotonin reuptake inhibitor (SSRI) indicated for: Acute and Maintenance Treatment of Major Depressive Disorder (MDD) in adults and adolescents aged 12-17 years (1.1) Acute Treatment of Generalized Anxiety Disorder (GAD) in adults (1.2)

Launch Date

1.02928318E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
63.4 nM
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
198.4 nM
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
58.6 nM
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
58 nM
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1109 nM × h
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3391 nM × h
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1102 nM × h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1964 nM × h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
29 h
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
32.5 h
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
26.6 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
26.7 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESCITALOPRAM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
44%
ESCITALOPRAM plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Disc. AE: Coma, Dizziness...
AEs leading to
discontinuation/dose reduction:
Coma (grade 3-4, 1 patient)
Dizziness (grade 1-2, 2 patients)
Restlessness (grade 1-2, 2 patients)
Agitation (grade 3-4, 4 patients)
Convulsion (grade 3-4, 1 patient)
Tremor (grade 1-2, 8 patients)
Mydriasis (grade 1-2, 3 patients)
Tachycardia (grade 1-2, 7 patients)
Change in ECG (grade 1-2, 4 patients)
Change in ECG (grade 3-4, 1 patient)
Nausea (grade 1-2, 4 patients)
Vomiting (grade 1-2, 8 patients)
Vomiting (grade 3-4, 1 patient)
Intestinal atony (grade 3-4, 1 patient)
Urinary retention (grade 3-4, 1 patient)
Somnolence (grade 1-2, 25 patients)
Sources:
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Disc. AE: Clonus, Clonus...
AEs leading to
discontinuation/dose reduction:
Clonus (12 patients)
Clonus (2 patients)
Hyperreflexia (21 patient)
Myoclonus (3 patients)
Eyelid myoclonus (2 patients)
Hunter's syndrome (7 patients)
Sources:
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Disc. AE: Clonus, Hyperreflexia...
AEs leading to
discontinuation/dose reduction:
Clonus (3 patients)
Hyperreflexia (9 patients)
Eyelid myoclonus (2 patients)
Hunter's syndrome (1 patient)
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 46.2 years
n = 4185
Health Status: unhealthy
Condition: Psychiatric diagnoses
Age Group: 46.2 years
Sex: M+F
Population Size: 4185
Sources:
Disc. AE: Coronary heart disease...
AEs leading to
discontinuation/dose reduction:
Coronary heart disease (10.7%)
Sources:
33.8 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 33.8 mg, 1 times / day
Route: oral
Route: steady
Dose: 33.8 mg, 1 times / day
Sources:
unhealthy, adult
n = 64
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 64
Sources:
Other AEs: Dry mouth, Sexual desire decreased...
Other AEs:
Dry mouth (8 patients)
Sexual desire decreased (21 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness grade 1-2, 2 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Restlessness grade 1-2, 2 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Somnolence grade 1-2, 25 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Mydriasis grade 1-2, 3 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Change in ECG grade 1-2, 4 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Nausea grade 1-2, 4 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Tachycardia grade 1-2, 7 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Tremor grade 1-2, 8 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Vomiting grade 1-2, 8 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Change in ECG grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Coma grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Convulsion grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Intestinal atony grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Urinary retention grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Vomiting grade 3-4, 1 patient
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Agitation grade 3-4, 4 patients
Disc. AE
332 mg single, oral (mean)
Overdose
Dose: 332 mg
Route: oral
Route: single
Dose: 332 mg
Sources:
unknown, 16 - 84 years
n = 63
Health Status: unknown
Age Group: 16 - 84 years
Sex: M+F
Population Size: 63
Sources:
Clonus 12 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Clonus 2 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Eyelid myoclonus 2 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Hyperreflexia 21 patient
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Myoclonus 3 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Hunter's syndrome 7 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Sources:
unknown, 18 - 36 years
n = 46
Health Status: unknown
Age Group: 18 - 36 years
Sex: M+F
Population Size: 46
Sources:
Hunter's syndrome 1 patient
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Eyelid myoclonus 2 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Clonus 3 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Hyperreflexia 9 patients
Disc. AE
140 mg single, oral (median)
Overdose
Dose: 140 mg
Route: oral
Route: single
Dose: 140 mg
Co-administed with::
coingested drugs
Sources:
unknown, 24 - 43 years
n = 33
Health Status: unknown
Age Group: 24 - 43 years
Sex: M+F
Population Size: 33
Sources:
Coronary heart disease 10.7%
Disc. AE
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 46.2 years
n = 4185
Health Status: unhealthy
Condition: Psychiatric diagnoses
Age Group: 46.2 years
Sex: M+F
Population Size: 4185
Sources:
Sexual desire decreased 21 patient
33.8 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 33.8 mg, 1 times / day
Route: oral
Route: steady
Dose: 33.8 mg, 1 times / day
Sources:
unhealthy, adult
n = 64
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 64
Sources:
Dry mouth 8 patients
33.8 mg 1 times / day steady, oral (mean)
Highest studied dose
Dose: 33.8 mg, 1 times / day
Route: oral
Route: steady
Dose: 33.8 mg, 1 times / day
Sources:
unhealthy, adult
n = 64
Health Status: unhealthy
Condition: obsessive-compulsive disorder
Age Group: adult
Sex: M+F
Population Size: 64
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
no
yes [IC50 70 uM]
yes (co-administration study)
Comment: coadministration of metoprolol with escitalopram increased concetrations of metoprolol (p50 of clinical pharmacology review)
Page: 70.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes [Km 29 uM]
yes (co-administration study)
Comment: coadministration of escitalopram with desipramine resulted in a 50% increase in desipramine concentraitons
Page: 70.0
yes [Km 588 uM]
yes [Km 69 uM]
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
New single-isomer compounds on the horizon.
2002 Apr
Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
2002 Apr
Escitalopram: a second-generation SSRI.
2002 Apr
Great expectations in stereochemistry: focus on antidepressants.
2002 Apr
A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway.
2003
Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions.
2004
A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
2004
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study.
2004
Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
2004
New formulations of existing antidepressants: advantages in the management of depression.
2004
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
2004
Spotlight on the pharmacoeconomics of escitalopram in depression.
2004
Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique.
2004 Apr
"Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review.
2004 Aug
Gateways to clinical trials.
2004 Dec
A case of hyponatremia associated with escitalopram.
2004 Dec
Selective binding of 2-[125I]iodo-nisoxetine to norepinephrine transporters in the brain.
2004 Jul
Escitalopram versus citalopram: the surprising role of the R-enantiomer.
2004 Jul
Gateways to clinical trials.
2004 Jul-Aug
Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.
2004 Jun
Escitalopram in trichotillomania.
2004 Jun
Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors.
2004 Jun
[Escitalopram--second generation of serotonin transporter inhibitors?].
2004 Mar-Apr
[Escitalopram: a chiral agent for treatment of depression].
2004 May
Antidepressant-associated mania with escitalopram.
2004 Nov
Liquid chromatography--electrospray ionisation mass spectrometry method for the determination of escitalopram in human plasma and its application in bioequivalence study.
2004 Nov 25
Venous thromboembolism and escitalopram.
2004 Nov-Dec
Gateways to clinical trials.
2004 Oct
The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels.
2004 Oct 22
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
2004 Sep
Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression.
2004 Sep
Evidence based review of escitalopram in treating major depressive disorder in primary care.
2004 Sep
Reformulation of consumer health queries with professional terminology: a pilot study.
2004 Sep 3
Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting.
2005
Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
2005
Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options.
2005
The safety of newer antidepressants in pregnancy and breastfeeding.
2005
An open-label trial of escitalopram in pervasive developmental disorders.
2005 Apr
Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies.
2005 Dec
A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
2005 Jan
Escitalopram intoxication.
2005 Jan
Quetiapine-induced weight gain and escitalopram.
2005 Jan
Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV.
2005 Jan
Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain.
2005 Jul
Evidence-based pharmacotherapy of Generalized Anxiety Disorder.
2005 Jun
Treatment of Raynaud's phenomenon with escitalopram.
2005 Jun
Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study.
2005 Mar
The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
2005 Mar
Escitalopram and suicidality in adult depression and anxiety.
2005 May
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
2005 May
Patents

Sample Use Guides

Lexapro (escitalopram) should generally be administered once daily, morning or evening with or without food. Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily
Route of Administration: Oral
Escitalopram blocked human hERG currents expressed in human embryonic kidney cells in a concentration-dependent manner with an IC50 value of 2.6 uM
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:08:15 UTC 2021
Edited
by admin
on Fri Jun 25 21:08:15 UTC 2021
Record UNII
4O4S742ANY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESCITALOPRAM
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
ESCITALOPRAM [VANDF]
Common Name English
CIPRALEX
Brand Name English
(+)-(S)-1-(3-(DIMETHYLAMINO)PROPYL)-1-(P-FLUOROPHENYL)-5-PHTHALANCARBONITRILE
Common Name English
ESCITALOPRAM [EP MONOGRAPH]
Common Name English
S-(+)-5-ISOBENZOFURANCARBONITRILE, 1-(3-(DIMETHYLAMINO)PROPYL)-1-(4-FLUOROPHENYL)-1,3-DIHYDRO-
Common Name English
ESITOL
Brand Name English
S-(+)-1-(3-(DIMETHYLAMINO)PROPYL)-1-(P-FLUOROPHENYL)-5-PHTHALANCARBONITRILE
Common Name English
ESCITALOPRAM [MI]
Common Name English
ESCITALOPRAM [INN]
Common Name English
ESCITALOPRAM [WHO-DD]
Common Name English
LU-26-054
Code English
ESERTIA
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
WHO-ATC N06AB10
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
LIVERTOX 368
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
NCI_THESAURUS C94725
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
NDF-RT N0000175696
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
NDF-RT N0000000109
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
WHO-VATC QN06AB10
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1053
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
ChEMBL
CHEMBL1508
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
LACTMED
Escitalopram
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
DRUG BANK
DB01175
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
EVMPD
SUB44650
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
WIKIPEDIA
ESCITALOPRAM
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
RXCUI
321988
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY RxNorm
FDA UNII
4O4S742ANY
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
EVMPD
SUB16425MIG
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
INN
7953
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
NCI_THESAURUS
C61754
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
PUBCHEM
146570
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
IUPHAR
7177
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
CAS
128196-01-0
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
EPA CompTox
128196-01-0
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY
MERCK INDEX
M3587
Created by admin on Fri Jun 25 21:08:15 UTC 2021 , Edited by admin on Fri Jun 25 21:08:15 UTC 2021
PRIMARY Merck Index
Related Record Type Details
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
RACEMATE -> ENANTIOMER
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE INACTIVE -> PARENT
The principal metabolite of escitalopram is Sdemethylcitalopram (S-DCT), which may be further metabolized to S-didemethylcitalopram (S-DDCT) in small quantities.
METABOLITE INACTIVE -> PARENT
The principal metabolite of escitalopram is Sdemethylcitalopram (S-DCT), which may be further metabolized to S-didemethylcitalopram (S-DDCT) in small quantities.
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ESCITALOPRAM OXALATE (ELDERLY)
PHARMACOKINETIC
CITALOPRAM, REDUCED HEPATIC FUNCITON
PHARMACOKINETIC
BIOAVAILABILITY PHARMACOKINETIC
Tmax PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY